French clinical study attributes Hypersensitivity to electromagnetic fieldsConsistent with commitments made following the round table “RF, health, environment,” a study to evaluate a protocol of specialized care of patients with idiopathic environmental intolerance (“hypersensitivity”) attributed to electromagnetic fields began in February 2012.

This is an independent pilot study, lasting 44 months, publicly funded in the framework of a National Hospital Clinical Research (PHRC 2010). Led by the Department of Professional Pathology of the Cochin-Broca-Hotel Dieu Hospital Group, it is organized by Assistance Publique – Hôpitaux de Paris (AP-HP), in collaboration with the National Institute for Industrial Environment and Risks (INERIS) and the National Agency for Sanitary Security of Food, Environment and Labour (HANDLE).

This multicenter national study will evaluate the sensitivity of patients to electromagnetic fields exposure as well as their state of health and quality of life. Patients will be received in their regional counseling centers for professional pathology and environment. Several medical consultations are scheduled according to a harmonized protocol at the national level to gather symptoms, characterize and measure exposures to EMF for a week and to assess the impact of suffering including psychological and social impacts. Monitoring of symptoms is planned for a year. Participation in this research is entirely voluntary. It is free.

To be part of the study, individuals can take an appointment in one of 24 clinics of occupational and environmental pathology, spread throughout France: Picardie, Ile-de-France, Aquitaine (Bordeaux, Poitiers ), Brittany (Brest, Rennes), Normandy (Caen, Rouen, Le Havre), Auvergne (Clermont-Ferrand), Rhone-Alpes (Lyon, Grenoble, St Etienne), Nord-Pas de Calais, Provence Côte d’Azur, Alsace-Lorraine, Pays de la Loire (Nantes), Champagne-Ardenne (Reims), Midi-Pyrenees.

The AP-HP has considered all the provisions of the law for the protection of people participating in biomedical research. The favorable opinion of the Committee of Protection of Persons for this research was obtained as well as authorization from the French Agency for Sanitary Safety of Health Products (AFSSAPS).